Hyperhomocysteinemia ||| S:0 E:20 ||| NNP
:  ||| S:20 E:22 ||| :
a  ||| S:22 E:24 ||| DT
biochemical  ||| S:24 E:36 ||| JJ
link  ||| S:36 E:41 ||| NN
between  ||| S:41 E:49 ||| IN
bone  ||| S:49 E:54 ||| NN
and  ||| S:54 E:58 ||| CC
cardiovascular  ||| S:58 E:73 ||| JJ
system  ||| S:73 E:80 ||| NN
diseases ||| S:80 E:88 ||| NNS
?  ||| S:88 E:90 ||| .
Homocysteine  ||| S:90 E:103 ||| NNP
( ||| S:103 E:104 ||| -LRB-
HCY ||| S:104 E:107 ||| NNP
)  ||| S:107 E:109 ||| -RRB-
is  ||| S:109 E:112 ||| VBZ
a  ||| S:112 E:114 ||| DT
sulfur-containing  ||| S:114 E:132 ||| JJ
amino  ||| S:132 E:138 ||| JJ
acid  ||| S:138 E:143 ||| NN
involved  ||| S:143 E:152 ||| VBN
in  ||| S:152 E:155 ||| IN
two  ||| S:155 E:159 ||| CD
metabolic  ||| S:159 E:169 ||| JJ
pathways ||| S:169 E:177 ||| NN
,  ||| S:177 E:179 ||| ,
catalized  ||| S:179 E:189 ||| VBG
by  ||| S:189 E:192 ||| IN
cystathionine-B-synthase  ||| S:192 E:217 ||| JJ
and  ||| S:217 E:221 ||| CC
methionine  ||| S:221 E:232 ||| JJ
synthase ||| S:232 E:240 ||| NN
,  ||| S:240 E:242 ||| ,
depending  ||| S:242 E:252 ||| VBG
on  ||| S:252 E:255 ||| IN
vitamin  ||| S:255 E:263 ||| NNS
( ||| S:263 E:264 ||| -LRB-
vit ||| S:264 E:267 ||| LS
)  ||| S:267 E:269 ||| -RRB-
B6 ||| S:269 E:271 ||| NNP
,  ||| S:271 E:273 ||| ,
B12 ||| S:273 E:276 ||| NNP
,  ||| S:276 E:278 ||| ,
and  ||| S:278 E:282 ||| CC
folate  ||| S:282 E:289 ||| JJ
levels  ||| S:289 E:296 ||| NNS
and  ||| S:296 E:300 ||| CC
enzymatic  ||| S:300 E:310 ||| JJ
activity  ||| S:310 E:319 ||| NN
of  ||| S:319 E:322 ||| IN
methylenetetrahydrofolate ||| S:322 E:347 ||| NN
.  ||| S:347 E:349 ||| .
High  ||| S:349 E:354 ||| NNP
HCY  ||| S:354 E:358 ||| NNP
levels  ||| S:358 E:365 ||| NNS
( ||| S:365 E:366 ||| -LRB-
HHCY ||| S:366 E:370 ||| NNP
)  ||| S:370 E:372 ||| -RRB-
are  ||| S:372 E:376 ||| VBP
associated  ||| S:376 E:387 ||| VBN
with  ||| S:387 E:392 ||| IN
cardiovascular  ||| S:392 E:407 ||| JJ
( ||| S:407 E:408 ||| -LRB-
CV ||| S:408 E:410 ||| NNP
)  ||| S:410 E:412 ||| -RRB-
and  ||| S:412 E:416 ||| CC
bone  ||| S:416 E:421 ||| NN
diseases ||| S:421 E:429 ||| NNS
,  ||| S:429 E:431 ||| ,
in  ||| S:431 E:434 ||| IN
particular  ||| S:434 E:445 ||| JJ
osteoporosis  ||| S:445 E:458 ||| NNS
( ||| S:458 E:459 ||| -LRB-
OP ||| S:459 E:461 ||| NNP
) ||| S:461 E:462 ||| -RRB-
/ ||| S:462 E:463 ||| FW
hip  ||| S:463 E:467 ||| FW
fracture ||| S:467 E:475 ||| FW
.  ||| S:475 E:477 ||| .
As  ||| S:477 E:480 ||| RB
regards  ||| S:480 E:488 ||| VBZ
the  ||| S:488 E:492 ||| DT
mechanisms  ||| S:492 E:503 ||| NNS
involved  ||| S:503 E:512 ||| VBN
in  ||| S:512 E:515 ||| IN
the  ||| S:515 E:519 ||| DT
link  ||| S:519 E:524 ||| NN
between  ||| S:524 E:532 ||| IN
HHCY ||| S:532 E:536 ||| NNP
,  ||| S:536 E:538 ||| ,
CV  ||| S:538 E:541 ||| NNP
diseases  ||| S:541 E:550 ||| NNS
( ||| S:550 E:551 ||| -LRB-
CVD ||| S:551 E:554 ||| NNP
) ||| S:554 E:555 ||| -RRB-
,  ||| S:555 E:557 ||| ,
and  ||| S:557 E:561 ||| CC
OP ||| S:561 E:563 ||| NNP
,  ||| S:563 E:565 ||| ,
it  ||| S:565 E:568 ||| PRP
has  ||| S:568 E:572 ||| VBZ
been  ||| S:572 E:577 ||| VBN
proposed  ||| S:577 E:586 ||| VBN
the  ||| S:586 E:590 ||| DT
role  ||| S:590 E:595 ||| NN
of  ||| S:595 E:598 ||| IN
lysyl-oxydase  ||| S:598 E:612 ||| JJ
inhibition  ||| S:612 E:623 ||| NN
that  ||| S:623 E:628 ||| WDT
might  ||| S:628 E:634 ||| MD
interfere  ||| S:634 E:644 ||| VB
with  ||| S:644 E:649 ||| IN
collagen  ||| S:649 E:658 ||| JJ
crosslink  ||| S:658 E:668 ||| JJ
formation ||| S:668 E:677 ||| NN
.  ||| S:677 E:679 ||| .
Some  ||| S:679 E:684 ||| DT
studies  ||| S:684 E:692 ||| NNS
suggested  ||| S:692 E:702 ||| VBD
the  ||| S:702 E:706 ||| DT
dysregulation  ||| S:706 E:720 ||| NN
of  ||| S:720 E:723 ||| IN
the  ||| S:723 E:727 ||| DT
osteoprotegerin ||| S:727 E:742 ||| JJ
/ ||| S:742 E:743 ||| CD
receptor  ||| S:743 E:752 ||| NN
activator  ||| S:752 E:762 ||| NN
of  ||| S:762 E:765 ||| IN
nuclear  ||| S:765 E:773 ||| JJ
factor-kappaB  ||| S:773 E:787 ||| NN
( ||| S:787 E:788 ||| -LRB-
RANK ||| S:788 E:792 ||| NNP
)  ||| S:792 E:794 ||| -RRB-
ligand ||| S:794 E:800 ||| FW
/ ||| S:800 E:801 ||| FW
RANK  ||| S:801 E:806 ||| FW
axis ||| S:806 E:810 ||| FW
,  ||| S:810 E:812 ||| ,
others  ||| S:812 E:819 ||| NNS
the  ||| S:819 E:823 ||| DT
involvement  ||| S:823 E:835 ||| NN
of  ||| S:835 E:838 ||| IN
oxidative  ||| S:838 E:848 ||| JJ
stress ||| S:848 E:854 ||| NN
.  ||| S:854 E:856 ||| .
These  ||| S:856 E:862 ||| DT
mechanisms  ||| S:862 E:873 ||| NNS
may  ||| S:873 E:877 ||| MD
act  ||| S:877 E:881 ||| VB
both  ||| S:881 E:886 ||| DT
on  ||| S:886 E:889 ||| IN
bone  ||| S:889 E:894 ||| NN
and  ||| S:894 E:898 ||| CC
CV  ||| S:898 E:901 ||| NNP
system ||| S:901 E:907 ||| NN
,  ||| S:907 E:909 ||| ,
but  ||| S:909 E:913 ||| CC
whether  ||| S:913 E:921 ||| IN
the  ||| S:921 E:925 ||| DT
common  ||| S:925 E:932 ||| JJ
denominator  ||| S:932 E:944 ||| NN
is  ||| S:944 E:947 ||| VBZ
HCY  ||| S:947 E:951 ||| NNP
itself  ||| S:951 E:958 ||| PRP
or  ||| S:958 E:961 ||| CC
HCY  ||| S:961 E:965 ||| NNP
is  ||| S:965 E:968 ||| VBZ
merely  ||| S:968 E:975 ||| RB
a  ||| S:975 E:977 ||| DT
marker ||| S:977 E:983 ||| NN
,  ||| S:983 E:985 ||| ,
remains  ||| S:985 E:993 ||| VBZ
to  ||| S:993 E:996 ||| TO
be  ||| S:996 E:999 ||| VB
clearly  ||| S:999 E:1007 ||| RB
established ||| S:1007 E:1018 ||| VBN
.  ||| S:1018 E:1020 ||| .
Folate ||| S:1020 E:1026 ||| NNP
,  ||| S:1026 E:1028 ||| ,
vit  ||| S:1028 E:1032 ||| CD
B6 ||| S:1032 E:1034 ||| CD
,  ||| S:1034 E:1036 ||| ,
and  ||| S:1036 E:1040 ||| CC
B12  ||| S:1040 E:1044 ||| CD
supplementation  ||| S:1044 E:1060 ||| NN
is  ||| S:1060 E:1063 ||| VBZ
associated  ||| S:1063 E:1074 ||| VBN
with  ||| S:1074 E:1079 ||| IN
HCY  ||| S:1079 E:1083 ||| NNP
reduction ||| S:1083 E:1092 ||| NN
,  ||| S:1092 E:1094 ||| ,
but  ||| S:1094 E:1098 ||| CC
is  ||| S:1098 E:1101 ||| VBZ
unable  ||| S:1101 E:1108 ||| JJ
to  ||| S:1108 E:1111 ||| TO
certainly  ||| S:1111 E:1121 ||| RB
reduce  ||| S:1121 E:1128 ||| VB
the  ||| S:1128 E:1132 ||| DT
incidence  ||| S:1132 E:1142 ||| NN
of  ||| S:1142 E:1145 ||| IN
OP ||| S:1145 E:1147 ||| NNP
/ ||| S:1147 E:1148 ||| NNP
fracture  ||| S:1148 E:1157 ||| NN
and  ||| S:1157 E:1161 ||| CC
CVD ||| S:1161 E:1164 ||| NNP
,  ||| S:1164 E:1166 ||| ,
probably  ||| S:1166 E:1175 ||| RB
because ||| S:1175 E:1182 ||| RB
,  ||| S:1182 E:1184 ||| ,
in  ||| S:1184 E:1187 ||| IN
the  ||| S:1187 E:1191 ||| DT
majority  ||| S:1191 E:1200 ||| NN
of  ||| S:1200 E:1203 ||| IN
patients ||| S:1203 E:1211 ||| NNS
,  ||| S:1211 E:1213 ||| ,
HCY  ||| S:1213 E:1217 ||| NNP
is  ||| S:1217 E:1220 ||| VBZ
only  ||| S:1220 E:1225 ||| RB
moderately  ||| S:1225 E:1236 ||| RB
increased ||| S:1236 E:1245 ||| VBN
.  ||| S:1245 E:1247 ||| .
